A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age
Latest Information Update: 08 Aug 2023
Price :
$35 *
At a glance
- Drugs MT-2271 (Primary)
- Indications Influenza A virus infections; Influenza B virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Medicago
- 10 Feb 2021 Primary endpoint has been met. (Immunogenicity will be evaluated by the immune response, as measured by change from baseline of the serum HI antibody titers)
- 10 Feb 2021 Results published in the Vaccine
- 23 Oct 2019 Status changed from recruiting to completed.